- Home
- BBUC vs HTFL Comparison
BBUC vs HTFL Comparison
Compare BBUC & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BBUC | HTFL |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | BBUC | HTFL |
|---|---|---|
| Price | $36.46 | $27.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $39.20 |
| AVG Volume (30 Days) | 87.9K | ★ 1.3M |
| Earning Date | 01-30-2026 | 03-27-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,168,000,000.00 | $161,881,000.00 |
| Revenue This Year | N/A | $40.42 |
| Revenue Next Year | N/A | $22.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 85.70 |
| 52 Week Low | $21.52 | $25.38 |
| 52 Week High | $37.89 | $41.22 |
Technical Indicators
Market Signals| Indicator | BBUC | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 30.33 |
| Support Level | $35.10 | $27.45 |
| Resistance Level | $37.47 | $30.19 |
| Average True Range (ATR) | 1.22 | 1.98 |
| MACD | 0.05 | -0.84 |
| Stochastic Oscillator | 59.12 | 1.35 |
Price Performance
Historical ComparisonAbout BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.